Iressa in the treatment of Brain Metastases from Non Small Cell Lung Cancer

Study identifier:1839IL/0569

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy

Medical condition

Brain Neoplasms

Phase

Phase 2

Healthy volunteers

Study drug

Iressa (Gefitinib)

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jul 2004

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Bologna, Italy

Location

Research Site

Parma, Italy

Location

Research Site

Rozzano, Italy

Location

Research Site

Orbassano, Italy

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Italy Study Information

+39 02 9801 6693

Investigators

Principal Investigator

Lucio Crino

Bologna, Italy

Iressa in the treatment of Brain Metastases from Non Small Cell Lung Cancer

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Research Site

Documents available

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator